Celcuity (NASDAQ:CELC) Shares Down 6.2% – Time to Sell?

Shares of Celcuity, Inc. (NASDAQ:CELC) traded down 6.2% during mid-day trading on Thursday . The stock traded as low as $106.64 and last traded at $107.3850. 298,092 shares changed hands during mid-day trading, a decline of 51% from the average session volume of 610,642 shares. The stock had previously closed at $114.48.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC set a $95.00 price objective on Celcuity in a research note on Monday, October 20th. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Wolfe Research began coverage on Celcuity in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Finally, Stifel Nicolaus raised their price objective on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $105.25.

Celcuity Trading Down 8.2%

The company has a 50 day moving average of $98.60 and a 200 day moving average of $64.04. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of -28.63 and a beta of 0.25. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. As a group, research analysts anticipate that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This represents a 30.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.77% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE raised its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the period. Rhumbline Advisers raised its holdings in Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the period. Ogorek Anthony Joseph NY ADV acquired a new stake in Celcuity during the third quarter worth approximately $27,000. Intech Investment Management LLC boosted its holdings in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after acquiring an additional 734 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.